为解决皮肤 T 细胞淋巴瘤（CTCL）治疗难题，研究人员探究 CD38 作用及联合疗法，发现联合治疗可提升疗效。 皮肤 T 细胞淋巴瘤（Cutaneous T-Cell Lymphoma，CTCL）是一种让人头疼的非霍奇金淋巴瘤，它专门 “攻击” 皮肤里的恶性 T 细胞。得了这种病，患者皮肤状况 ...

While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab’s rigorous portfolio ...

Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter company to discontinue development of the program. Back in 2019 ...

Despite initial clinical data showing efficacy, Genmab has decided to discontinue further clinical development of ...

Despite initial clinical data showing efficacy, Genmab has decided to discontinue further clinical development of HexaBody-CD38. “While we are disappointed that J&J has decided not to advance ...